PCSK9 and aortic stenosis: In addition, patients with elevated Lp(a) levels also demonstrate faster disease progression [36] and, in an exploratory analysis of clinical trials of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition, higher Lp(a) levels, but not Lp(a)-corrected LDL cholesterol levels, were found to be associated with a higher risk of subsequent AS events [37].